High-dose statins did not increase the risk of kidney injury after heart attack, according to two randomized, clinical trials.
The first trial, PROVE IT-TIMI, randomly assigned 4,162 patients to double-blinded doses of 80 mg atorvastatin compared to 40 mg pravastatin to prevent major adverse coronary events following acute coronary syndrome.
A second trial, A to Z, randomly assigned 4,497 patients to double-blinded doses of simvastatin 40 mg for 1 month, then simvastatin 80 mg after, compared to delayed initiation of a placebo for 4 months, then simvastatin 20 mg.
The preliminary research was presented at the American Heart Association's Emerging Science Series Webinar and published in Circulation.
The two trials showed that relative changes in serum creatinine and incidence of kidney disease over time were the same, and when data from the two trials was combined, the rate of adverse events of intensive vs. les intensive statin therapy was 0.92% vs. 0.91% (P=0.97).
"These findings provide important reassurance to clinicians that the use of some high-potency statins will not increase the risk of kidney injury," said the study author in a press release.
In case you missed it
Medical Economics published its "subjective list of 10 internists who offer unique and engaging content to their followers on Twitter." Of note, six of the 10 are ACP members. Woot! For the complete list of ACP members who are using Twitter, click here.